Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

By N. Mohan, E. Edwards, T. Cupps, P. Oliverio, G. Sandberg, H. Crayton, J. Richert, J. Siegel. Arthritis & Rheumatism, 2001

890 citations recorded by the source corpus.

Subfields: Neurology, Pathology and Forensic Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/73bd324ec3fbf17ceecf409afcdb7dace0e447f4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Rheumatology

1. Martina Anzaghe
2. Yen-Ju Lin
3. S. Schülke

Citations in the corpus

• Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. (2006, background): “There are also important distinctions in the safety profiles between the groups, most notably an increased risk of intracellular infections rather specific to the TNF agent used(51) and a possible increased risk of certain neurological disorders in patients taking etanercept.(52) The heterogeneous m”
• Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis (2020, background): “In addition, usage of biological DMARDs may result in elevated levels of transaminases, induction or reactivation of autoimmune conditions such as multiple sclerosis and psoriasis, as well as worsening congestive heart failure [129,287,288].”
• Binding and functional comparisons of two types of tumor necrosis factor antagonists. (2002, background): “…in the safety profiles of these two products, most notably an increased risk of specific types of infection for infliximab (Keane et al., 2001) or etanercept (Fisher et al., 1996; Song et al., 2001), or possibly an increased risk of neurological disorders for etanercept (Mohan et al., 2001).”
• Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. (2008, positive): “Although some patients’ symptoms of demyelinating disease have abated despite continued TNF inhibition, other reports demonstrate that patients who develop neurologic symptoms suggestive of MS after treatment with a TNF inhibitor resolve after the TNF inhibitor is stopped.(150) Onset of new neurolog”
• Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS) (2011, background): “Moreover, demyelination has been reported in recipients of anti-TNF biologicals for other inflammatory diseases; these are contraindicated when these inflammatory conditions coexist with MS (Mohan et al., 2001).”